[
 {
  "title": "Overview of COVID-19 pandemic",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "Michael Osterholm, Director of the Center for Infectious Disease Research and Policy at the University of Minnesota and author of Deadliest Enemy: Our War Against Killer Germs, provides an overview on the COVID-19 pandemic in regards to what has happened to date, what we’ve learned about how the disease spreads, and his optimism and pessimism about what potentially lies ahead.",
  "content_length": 379,
  "content_tokens": 79,
  "embedding": []
 },
 {
  "title": "Case fatality rate and underlying conditions",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "Michael gives his take on the true case fatality rate, why it differs around the world, and which underlying conditions, such as obesity, impact risk of severe illness and death.",
  "content_length": 178,
  "content_tokens": 36,
  "embedding": []
 },
 {
  "title": "Outlook on vaccines and treatment",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "We also discuss the outlook regarding vaccines, repurposed drugs/antivirals for treatment, and Michael’s growing concern about supply chain limitations with respect to drugs, vaccines, n95 masks, and testing kits.",
  "content_length": 213,
  "content_tokens": 46,
  "embedding": []
 },
 {
  "title": "Recapping the brief history of COVID-19 and what potentially lies ahead",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "Recapping the brief history of COVID-19 and what potentially lies ahead [2:15];",
  "content_length": 79,
  "content_tokens": 20,
  "embedding": []
 },
 {
  "title": "Some positive news about immunity and reinfection",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "Some positive news about immunity and reinfection [10:45];",
  "content_length": 58,
  "content_tokens": 14,
  "embedding": []
 },
 {
  "title": "Case fatality rate—the challenge in finding the true rate, difference by country, and the impact of age, underlying conditions, and obesity",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "Case fatality rate—the challenge in finding the true rate, difference by country, and the impact of age, underlying conditions, and obesity [13:00];",
  "content_length": 148,
  "content_tokens": 33,
  "embedding": []
 },
 {
  "title": "What has to be true for less than 100,000 Americans to die from COVID-19?",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "What has to be true for less than 100,000 Americans to die from COVID-19? [24:30];",
  "content_length": 82,
  "content_tokens": 25,
  "embedding": []
 },
 {
  "title": "How do we best protect healthcare workers?",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "How do we best protect healthcare workers? [29:45];",
  "content_length": 51,
  "content_tokens": 13,
  "embedding": []
 },
 {
  "title": "Concerns about testing capability—reagent shortfall and a supply chain problem",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "Concerns about testing capability—reagent shortfall and a supply chain problem [39:30];",
  "content_length": 87,
  "content_tokens": 20,
  "embedding": []
 },
 {
  "title": "Vaccines and antivirals—The outlook, timing, and challenges",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "Vaccines and antivirals—The outlook, timing, and challenges [47:45];",
  "content_length": 68,
  "content_tokens": 20,
  "embedding": []
 },
 {
  "title": "Long term health of survivors of COVID-19",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "Long term health of survivors of COVID-19 [56:45];",
  "content_length": 50,
  "content_tokens": 15,
  "embedding": []
 },
 {
  "title": "The impact of comorbidities—Diabetes, obesity, and immunosuppressed patients",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "The impact of comorbidities—Diabetes, obesity, and immunosuppressed patients [59:30];",
  "content_length": 85,
  "content_tokens": 24,
  "embedding": []
 },
 {
  "title": "Understanding R0 and how the disease spreads",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "Understanding R0 and how the disease spreads [1:01:30];",
  "content_length": 55,
  "content_tokens": 15,
  "embedding": []
 },
 {
  "title": "The challenge of forecasting with so many unknowns",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "The challenge of forecasting with so many unknowns [1:08:00];",
  "content_length": 61,
  "content_tokens": 16,
  "embedding": []
 },
 {
  "title": "What explains the difference in cases and fatalities in different parts of the world?",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "What explains the difference in cases and fatalities in different parts of the world? [1:14:30];",
  "content_length": 96,
  "content_tokens": 22,
  "embedding": []
 },
 {
  "title": "Repurposed drugs/antivirals being considered for treatment options—any optimism?",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "Repurposed drugs/antivirals being considered for treatment options—any optimism? [1:16:45];",
  "content_length": 91,
  "content_tokens": 25,
  "embedding": []
 },
 {
  "title": "A parting message from Michael about what lies ahead",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "A parting message from Michael about what lies ahead [1:18:30];",
  "content_length": 63,
  "content_tokens": 16,
  "embedding": []
 },
 {
  "title": "The Impact of Stress on Our Physical and Emotional Health",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "Robert Sapolsky, Ph.D., discusses the widespread impact of stress on our physical and emotional health as well as the mechanisms by which it can precipitate chronic illness, dementia, depression, and more.",
  "content_length": 205,
  "content_tokens": 42,
  "embedding": []
 },
 {
  "title": "The Impact of Stress on Chronic Illness, Dementia, Depression, and More",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "Robert Sapolsky, Ph.D., discusses the widespread impact of stress on our physical and emotional health as well as the mechanisms by which it can precipitate chronic illness, dementia, depression, and more.",
  "content_length": 205,
  "content_tokens": 42,
  "embedding": []
 },
 {
  "title": "Physiology of a Stress Response",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "Robert Sapolsky explains the physiology of a stress response and why it’s ingrained in our DNA.",
  "content_length": 95,
  "content_tokens": 22,
  "embedding": []
 },
 {
  "title": "Individual Variation in the Response to Stress",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "Robert Sapolsky talks about individual variation in the response to stress and how everyone has a different optimal level.",
  "content_length": 122,
  "content_tokens": 22,
  "embedding": []
 },
 {
  "title": "The Impact of Stress on Memory and Health",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "Robert Sapolsky discusses the role of stress on memory and the consequences of hypercortisolemia, as well as the impact of subjective socioeconomic status and social media on stress levels and health.",
  "content_length": 200,
  "content_tokens": 40,
  "embedding": []
 },
 {
  "title": "The Impact of Stress on Cancer, Atherosclerosis, Dementia, Addiction, and Depression",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "Robert Sapolsky talks about the impact of stress on cancer, atherosclerosis, dementia, addiction, and depression.",
  "content_length": 113,
  "content_tokens": 24,
  "embedding": []
 },
 {
  "title": "Brief history of COVID-19",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "COVID-19 appeared in December 2019 in China and is different from SARS and MERS because it can be transmitted before symptoms occur much more like influenza. Michael predicted this would be a pandemic in early February. It's unclear if it will be seasonal or spread year-round.",
  "content_length": 277,
  "content_tokens": 58,
  "embedding": []
 },
 {
  "title": "How long will COVID-19 be around?",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "Michael says it’s unlikely to “go away” until 60-70% of the population gets infected. In the US, we’re unlikely to be able to forcibly lock people down like they did in China (nor should we). Until there’s a vaccine, it’s hard to see how this virus doesn’t hit a majority of the US population (60-70%).",
  "content_length": 302,
  "content_tokens": 86,
  "embedding": []
 },
 {
  "title": "A second wave?",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "Until there’s a vaccine, it’s hard to see how this virus doesn’t hit a majority of the US population (60-70%) because once we come out of sheltering it might spread again (like people speculate is happening in China).",
  "content_length": 217,
  "content_tokens": 55,
  "embedding": []
 },
 {
  "title": "Case fatality rate",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "There is a challenge in finding the true case fatality rate, which differs by country, and the impact of age, underlying conditions, and obesity. A Lancet paper has updated case fatality information from China.",
  "content_length": 210,
  "content_tokens": 42,
  "embedding": []
 },
 {
  "title": "Revised CFR",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "The revised CFR now looks to be 0.66%. This was down from 1.38% before they added a bunch more people to the denominator that were previously in the unconfirmed bucket.",
  "content_length": 168,
  "content_tokens": 39,
  "embedding": []
 },
 {
  "title": "Underlying conditions and comorbidities",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "In China, many males over 65 were dying, but women weren’t. The difference? Smoking is prevalent in 70% of men and only 2% of women. Other risk factors include hypertension, renal disease, and obesity may be the highest risk factor for younger people who die. We’re seeing an increased number of severe illnesses and deaths in people between the ages of 25 and 50…and the risk factor appears to be obesity.",
  "content_length": 406,
  "content_tokens": 90,
  "embedding": []
 },
 {
  "title": "Mike’s estimate of the actual CFR",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "Mike thinks it’s likely to be in the 1.0-2.5% range. US has a large population over 65 and we have a lot of obesity in young people.",
  "content_length": 132,
  "content_tokens": 40,
  "embedding": []
 },
 {
  "title": "What has to be true for less than 100,000 Americans to die from COVID-19?",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "Two things, says Mike: 1—We have to basically suppress transmission as much as we can, which I don’t think is doable [long term]…as a country we can’t sustain that. This would destroy the economy. Mike’s op ed in the NY Times, he wrote about how this is not a choice between saving lives and costing the economy…it’s a combination of both. 2—We have to make sure the supply of critical care supplies and drugs are available. Mike is concerned that we will have shortage of those things leading to unnecessary death.",
  "content_length": 515,
  "content_tokens": 123,
  "embedding": []
 },
 {
  "title": "How do we best protect healthcare workers?",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "The main thing is we need all healthcare workers supplied with an n95 mask. There is some confusion that a surgical mask is sufficient (not the case). An n95 mask stops aerosols. But we don’t have nearly enough to match the demand despite 3m trying to ramp up production. Mike and his team is working on a technique to make that possible. One more solution: What can we do to get infected healthcare workers back? Once they are immune they won’t require a mask.",
  "content_length": 461,
  "content_tokens": 103,
  "embedding": []
 },
 {
  "title": "Concerns about testing capability—reagent shortfall and a supply chain problem",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "The US has tested about 800,000 people so far. For the PCR tests (which look at whether you are currently infected), the test kits are mostly being provided by Roche. Mike is very concerned about the supply chain of the test kits and just as importantly, the reagents which are needed to get the results of the test.",
  "content_length": 316,
  "content_tokens": 67,
  "embedding": []
 },
 {
  "title": "Abbott tests",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "Some good news it Abbot is developing a new COVID-19 test. But Mike still remains concerned that we will have a shortfall of reagent water. So we might have plenty of tests but no way to get the results.",
  "content_length": 203,
  "content_tokens": 47,
  "embedding": []
 },
 {
  "title": "Vaccines and antivirals",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "In Peter’s discussion with biotech companies (off the record), nobody seems confident a vaccine will be ready any sooner than 12 months from now. Even more challenging than a vaccine might be creating an antiviral for treatment. Over the last 60 years, only ~5,000 antiviral drugs that we being approved, only about 90 were approved (and 40 were for HIV).",
  "content_length": 355,
  "content_tokens": 76,
  "embedding": []
 },
 {
  "title": "Long term health of survivors of COVID-19",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "Unfortunately, we know little about the possible side effects of having gotten and recovered from COVID-19. For example, we don’t understand how much lingering myocarditis is out there, how much lingering kidney disease is out there, and how much lingering lung disease remains in terms of fibrosis or maybe even permanent destruction of a subset of the pneumocytes.",
  "content_length": 366,
  "content_tokens": 74,
  "embedding": []
 },
 {
  "title": "The impact of comorbidities",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "Type 2 diabetes and obesity are both risk factors. Type 1 diabetes patients also seems to be at higher risk but it’s unclear why that’s the case. The data is all being revealed on this but as of today it does not appear that immunosuppressed people are at higher risk (e.g., HIV patients don’t seem at higher risk).",
  "content_length": 315,
  "content_tokens": 77,
  "embedding": []
 },
 {
  "title": "Understanding R0 and how the disease spreads",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "Mike alluded that average R0 is between 2 and 2.4. Peter wonders is symptomatic vs asymptomatic would have a different R0 and if we should be thinking about those cases differently. Mike says they are currently having that debate right now so it’s unclear.",
  "content_length": 256,
  "content_tokens": 58,
  "embedding": []
 },
 {
  "title": "Super Spreaders and R0",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "Mike challenges the relevance of R0 for MERS and SARS due to the existence of super spreaders. He explains that the super spreader is a property of the host, not the virus. With COVID-19, there is a hybrid of super spreader events and regular transmission. Mike believes that we have SARS-like super spreader events, but there is also a lot of efficient transmission.",
  "content_length": 367,
  "content_tokens": 83,
  "embedding": []
 },
 {
  "title": "Transmission and Aerosols",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "Transmission of COVID-19 could occur even with little to no symptoms due to the higher volume of virus in the throat. Aerosols from breathing and talking can spread the virus. Mike explains that aerosols are the same particles that we see floating in the air in our homes and in shopping centers. He also notes that presymptomatic people can be infectious before they show symptoms.",
  "content_length": 382,
  "content_tokens": 79,
  "embedding": []
 },
 {
  "title": "Forecasting and Models",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "Forecasting the outbreak is challenging due to the variability in the output of the models. Mike believes that all models are wrong, but some provide helpful information. He explains that the models are sensitive to variables like R0, which we don't know the probability distribution of. Therefore, it is incredibly challenging to allocate resources effectively.",
  "content_length": 362,
  "content_tokens": 65,
  "embedding": []
 },
 {
  "title": "Variations in cases and fatality rates in different parts of the world",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "Each country is fighting for the same supplies that are critical and in shortage so the lower income countries will likely not be able to get the same stuff. However, lower income countries will have less older people with underlying issues (who are the most susceptible to die from this) simply because of the fact that those people have already died in the country since the country doesn’t have the healthcare that we have in the US, for example. This implication is that the lower income country may have less fatality rate because of that.",
  "content_length": 544,
  "content_tokens": 106,
  "embedding": []
 },
 {
  "title": "Obesity and age",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "The countries will more obesity in the younger population may see an uptick. The countries with older populations will see an increase.",
  "content_length": 135,
  "content_tokens": 24,
  "embedding": []
 },
 {
  "title": "Repurposed drugs/antivirals being considered for treatment options—any optimism?",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "There was a study that was published out of France looking at hydroxychloroquine showing promise. But studies like these don’t have the luxury of being randomly controlled so it’s hard to take much from them. Mike admits that this is not his expertise but that he feels optimistic. “I do believe we’re going to have much more information on therapies much sooner than vaccines and that could be really important.”",
  "content_length": 413,
  "content_tokens": 91,
  "embedding": []
 },
 {
  "title": "Dr. Osterholm's Expertise",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "Dr. Osterholm is the director of the Center for Infectious Disease Research and Policy (CIDRAP) and a member of the National Academy of Medicine (NAM). He was appointed to the newly established National Science Advisory Board on Biosecurity and the World Economic Forum Working Group on Pandemics.",
  "content_length": 297,
  "content_tokens": 65,
  "embedding": []
 },
 {
  "title": "Disease",
  "date": "March 31, 2020",
  "context": "COVID-19",
  "people": "Peter Attia",
  "content": "Dr. Osterholm is the author of Deadliest Enemy: Our War Against Killer Germs",
  "content_length": 76,
  "content_tokens": 19,
  "embedding": []
 }
]